Article

Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 7:11

Institute of Cardiology, University of Bologna, Bolonia, Emilia-Romagna, Italy
BMC Developmental Biology (Impact Factor: 2.67). 02/2007; 7(1):11. DOI: 10.1186/1471-213X-7-11
Source: PubMed

ABSTRACT

Term Amniotic membrane (AM) is a very attractive source of Mesenchymal Stem Cells (MSCs) due to the fact that this fetal tissue is usually discarded without ethical conflicts, leading to high efficiency in MSC recovery with no intrusive procedures. Here we confirmed that term AM, as previously reported in the literature, is an abundant source of hMSCs; in particular we further investigated the AM differentiation potential by assessing whether these cells may also be committed to the angiogenic fate. In agreement with the recommendation of the International Society for Cellular Therapy, the mesenchymal cells herein investigated were named Amniotic Membrane-human Mesenchymal Stromal Cells (AM-hMSC).
The recovery of hMSCs and their in vitro expansion potential were greater in amniotic membrane than in bone marrow stroma. At flow cytometry analysis AM-hMSCs showed an immunophenotypical profile, i.e., positive for CD105, CD73, CD29, CD44, CD166 and negative for CD14, CD34, CD45, consistent with that reported for bone marrow-derived MSCs. In addition, amniotic membrane-isolated cells underwent in vitro osteogenic (von Kossa stain), adipogenic (Oil Red-O stain), chondrogenic (collagen type II immunohistochemichal detection) and myogenic (RT-PCR MyoD and Myogenin expression as well as desmin immunohistochemical detection) differentiation. In angiogenic experiments, a spontaneous differentiation into endothelial cells was detected by in vitro matrigel assay and this behaviour has been enhanced through Vascular Endothelial Growth Factor (VEGF) induction. According to these findings, VEGF receptor 1 and 2 (FLT-1 and KDR) were basally expressed in AM-hMSCs and the expression of endothelial-specific markers like FLT-1 KDR, ICAM-1 increased after exposure to VEGF together with the occurrence of CD34 and von Willebrand Factor positive cells.
The current study suggests that AM-hMSCs may emerge as a remarkable tool for the cell therapy of multiple diseased tissues. AM-hMSCs may potentially assist both bone and cartilage repair, nevertheless, due to their angiogenic potential, they may also pave the way for novel approaches in the development of tissue-engineered vascular grafts which are useful when vascularization of ischemic tissues is required.

Download full-text

Full-text

Available from: Giacomo Lanzoni
  • Source
    • "The human placenta is an important source of particularly the mesenchymal stem cells (MSCs), which represent less than one percent of its cells. These can be isolated from first-, second-, and third-trimester placental compartments, including the amnion, chorion, decidua parietalis, decidua basalis, and placental villi (Zhao et al., 2005; Alviano et al., 2007; Soncini et al., 2007; Pasquinelli et al., 2007; Parolini et al., 2010). The following hypothesis has been postulated " Because MSCs can inhibit the action of T-lymphocytes as well as the differentiation and proliferation of monocytes, they are not immunogenic " (Zhang et al., 2006a,b; Moore et al., 2003). "

    Full-text · Article · May 2015 · Tissue and Cell
  • Source
    • "Even though there is debate on the technical name (mesenchymal or multipotent stem cells), there is an agreement to the acronym " MSC " . Since their original description, presence of MSC has been proven in many adult and embryonic tissues such as adipose tissue [3], muscle [4], peripheral blood [5], lung [6], heart [7], corneal stroma [8], dental pulp [9], placenta [10], endometrium [11], amniotic membrane [12], and Wharton's jelly [13]. MSC have the capability to differentiate into wide range of specialized cells of mesodermal origin: bone cells, cartilage, fat, cardiomyocytes , muscle fibers, renal tubular cells, and break germ layer commitment and differentiate into cells of ectodermal origin, for example, neurons, and endodermal origin, such as hepatocytes and pancreatic islets cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Around 5 million annual births in EU and 131 million worldwide give a unique opportunity to collect lifesaving Wharton's jelly derived mesenchymal stem cells (WJ-MSC). Evidences that these cells possess therapeutic properties are constantly accumulating. Collection of WJ-MSC is done at the time of delivery and it is easy and devoid of side effects associated with collection of adult stem cells from bone marrow or adipose tissue. Likewise, their rate of proliferation, immune privileged status, lack of ethical concerns, nontumorigenic properties make them ideal for both autologous and allogeneic use in regenerative medicine applications. This review provides an outline of the recent findings related to WJ-MSC therapeutic effects and possible advantage they possess over MSC from other sources. Results of first clinical trials conducted to treat immune disorders are highlighted.
    Full-text · Article · Mar 2015 · BioMed Research International
  • Source
    • "The human placenta is an important source of particularly the mesenchymal stem cells (MSCs), which represent less than one percent of its cells. These can be isolated from first-, second-, and third-trimester placental compartments, including the amnion, chorion, decidua parietalis, decidua basalis, and placental villi (Zhao et al., 2005; Alviano et al., 2007; Soncini et al., 2007; Pasquinelli et al., 2007; Parolini et al., 2010). The following hypothesis has been postulated " Because MSCs can inhibit the action of T-lymphocytes as well as the differentiation and proliferation of monocytes, they are not immunogenic " (Zhang et al., 2006a,b; Moore et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: tBackground: Although the human placenta is considered medical wastes, it has become a main source ofstem cells. Due to their easy isolation, ability to resist immune rejection and ability to differentiate intodifferent types of adult cells, placental stem cells are considered superior to other stem cells.Objectives: This study aimed to assess the impact of the maternal age on the expression of mesenchymalstem cell (MSC) markers CD105 and CD29 in different areas of a term human placenta and to identify thedifferential expression of these markers in different placental areas.Subjects and methods: In this comparative cross sectional study, one hundred term placentas were col-lected after delivery from healthy mothers divided into five groups according to their age. Placentas wereprocessed to assess both immune- and gene-expression of CD105 and CD29 surface antigen markers. Dataof the different studied age groups was compared using the Statistical Package of Social Science (SPSS)software.Results: CD105 and CD29 immunoexpression in decidua basalis, fetal membrane and placental villishowed significant negative correlations with the maternal age. CD105- and CD29-positive MSCs weresignificantly abundant in the decidua basalis and placental villi. Real-time polymerase chain reactionresults were consistent with those of the immunohistochemical study.Conclusion: Labeling the placenta-driven MSCs with the specific area from which the cells were taken aswell as the mother’s age is advised and could be helpful in controlling the quality of the cell banks as wellas the favorable outcome of the therapeutic applications.
    Full-text · Article · Jan 2015 · Tissue and Cell
Show more